DocStoX is a free AI-powered research platform for Indian equity markets, covering 6,800+ NSE & BSE stocks with prices, fundamentals, 326 financial ratios, shareholding, FII/DII flows, F&O, IPOs, a visual screener and AI stock scoring.

Yes. DocStoX has a free tier covering stock research, the screener, FII/DII data and educational guides, plus a free MCP API tier (50 tool calls/day) for AI assistants. A Pro plan adds higher limits and advanced features.

What data does DocStoX cover?

Every NSE & BSE listed stock (6,800+ instruments): EOD and intraday prices, income statement / balance sheet / cash flow, 326 ratios, quarterly shareholding, promoter pledge, mutual-fund holdings, FII/DII flows, F&O and option-chain data, analyst forecasts, IPOs, corporate actions and news.

Can AI assistants like ChatGPT or Claude use DocStoX data?

Yes. DocStoX runs a public Model Context Protocol (MCP) server at https://mcp.docstox.com/mcp with 39 tools, so Claude, ChatGPT, Cursor and other MCP clients can pull Indian market data directly. Setup and a free key are at https://docstox.com/mcp.

What is the SYNGENE INTERNATIONAL LTD (SYNGENE) share price today?

SYNGENE INTERNATIONAL LTD (SYNGENE) is trading at ₹417.45 on the NSE, down 0.46% on the day. Source: DocStoX.

What is the PE ratio of SYNGENE INTERNATIONAL LTD?

SYNGENE INTERNATIONAL LTD has a price-to-earnings (PE) ratio of 35.9 in the Healthcare sector.

What is the market capitalisation of SYNGENE INTERNATIONAL LTD?

SYNGENE INTERNATIONAL LTD has a market capitalisation of approximately ₹16,819 crore.

SYNGENE INTERNATIONAL LTD

F&O

SYNGENE·NSE·Healthcare

₹417.45▼ -1.95 (-0.46%)

Healthcare · Healthcare Technology

A steady, established business

NIFTY 500NIFTY SMALLCAP 250

Day₹410.10

₹420.90

52W₹380

₹72911%

Open

₹420.90

High

₹420.90

Low

₹410.10

Prev Close

₹419.40

Volume

4.88L

VWAP

₹414.92

Snapshot

Key fundamentals

Market Cap

₹16,819 Cr

P/E Ratio

35.89Expensive

P/B Ratio

3.47

EPS

₹11.63

Book Value

₹119.90

ROE

11.98%Average

ROCE

13.00%Decent

Dividend Yield

0.29%

Debt / Equity

0.13Low

Face Value

₹10.00

52W High

₹728.60

52W Low

₹380.00

Sector

Healthcare

Industry

Healthcare Technology

Avoid

None moatMedium uncertainty

Fair value estimate

₹119

▼ 71.6%downside

Trading at ₹417 — 72% above our estimate

BearFair valueBull

₹101₹119₹143

/100

Business quality — Watch the fundamentals

Growth 1Profitability 50Efficiency 13Valuation 64

Plain English

Our view

A steady, established business
Low debt relative to equity
Fundamental red flags (Piotroski 2/9)

Strengths

Low debt relative to equity
Promoters hold a controlling stake

Risks

Fundamental red flags (Piotroski 2/9)

How we got there

Fair value methods

Residual income

6% ROE fading to 12% over ~3 yrs, on ₹120 book

₹112

Relative P/E

Needs ≥3 peers with P/E

—

Graham floor

Conservative floor: √(22.5 × EPS × book value/share)

₹143

Analyst target

No analyst coverage

—

Blended fair value₹119

What the numbers say

Investment thesis

Bull case

Low debt relative to equity
Promoters hold a controlling stake

Bear case

Fundamental red flags (Piotroski 2/9)

Free — see our deterministic Fair Value range, business quality score, and the full bull/bear case for this stock.

Snapshot

Key statistics

P/E

35.9Expensive

Below 15× is value territory; above 35× prices in strong growth

ROE

12.0%Average

Above 15% is considered healthy for Indian equities

ROCE

13.0%Decent

Above 18% means capital is working hard

Debt/Eq

0.13Low

Below 0.5 is comfortable; above 1.5 strains the balance sheet

Mkt Cap

₹16,819 Cr

P/B

3.47

EPS

₹11.63

Div Yield

0.29%

What changed

Recent changes

Foreign investors-1.1% stake last quarter
Domestic institutions+0.6% stake last quarter

What matters

News impact

Overview

Valuation

Expensive

P/E 35.9×

Growth

Slow

+2% rev CAGR

Profitability

Modest

12.0% ROE

Financial health

Rock solid

D/E 0.13

Momentum

N/A

No technicals

Today

Trading activity

Delivery %53.7%

Turnover₹2024.44L Cr

Trades25,458

VWAP₹414.92

Face value₹10.00

Market depth

Market depth available during market hours

Snapshot

Technical signals

Compounded annual growth

Growth (CAGR)

Revenue

+2.3%

+9.5%

10Y

+11.9%

Profit

-13.6%

-5.5%

10Y

+2.4%

EPS

-13.7%

-5.6%

10Y

+2.3%

Profile

Pros

Company has reduced debt.
Company is almost debt free.

Watch-outs

Cons

Stock is trading at 3.60 times its book value
The company has delivered a poor sales growth of 9.45% over past five years.
Company has a low return on equity of 9.56% over last 3 years.
Dividend payout has been low at 12.7% of profits over last 3 years

Forecast

News

Peers

Financials

Growth

Shareholding

Ownership

Ownership breakdown

Quarter ending 31 Mar 2026

Foreign investors sold 1.06 pts; domestic institutions added 0.60 pts last quarter. The QoQ column shows each group's change versus the prior quarter.

53%

Promoter

Promoters

52.7%0.00

Public

5.5%+0.14

FII / FPI

13.9%-1.06

DII

26.4%+0.60

Others

1.5%

Total shareholders

1,35,605+3,855 QoQ

Quarterly trend

Ownership over time

Q4 FY26

Promoter52.68%

FII13.90%

DII26.44%

Public5.51%

Others1.47%

Corporate Actions

Bulk & Block Deals

Filings

MF Holdings

Technicals

FAQs

Quick reference

Frequently asked questions

F&O